New licensing program facilitates adoption of Tandem Mass Tag technology

Thermo Fisher Scientific helps research service providers and their customers optimize protein identification and quantitation.

The Thermo Fisher Scientific licensing program enables service providers to leverage the power of Thermo Scientific TMT technology to cater to the analytical needs of their customers for more reproducible quantitative proteomics. Cell Signaling Technology (CST), a specialized provider of research products and services and an early licensee, is already realizing the benefits of the quantitative multiplex technology.

“There is an increased market demand for the unique analytical capabilities of the TMT technology, as well as for service providers with the necessary skills and equipment to perform that type of analysis. We are very excited about growing the use of this technology and having the ability to offer it through CST’s service business,” said Navid Haghdoost, director, Protein Biology Product Management, Thermo Fisher Scientific.

The TMT technology uses tandem mass spectrometry (MS/MS) to provide consistent and accurate simultaneous identification and quantitation of proteins in up to 10 different samples derived from cells, tissues or biological fluids. The technology features an enhanced multiplex capability resulting in fewer missing quantitative values as the level of TMT multiplexing increases.

“CST is pleased to license TMT technology from Thermo Fisher Scientific, which will add power to our proteomics services by delivering unparalleled quantitative protein analysis. We expect this technology will enable us to help our pharma and academic customers accelerate their pre-clinical discovery research,” said Roberto Polakiewicz, chief scientific officer at CST.